Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-23

Study Completion Date

2021-11-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single-center, randomized, open-label study to compare the pharmacokinetic profiles of Famitinib and its metabolite SHR116637 at different doses/specifications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer

NCT01829841

Renal Cell Cancer Metastatic Renal Cell Cancer

COMPLETED PHASE2

Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

NCT04409223

Gastrointestinal Stromal Tumors

TERMINATED PHASE3

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

NCT03827837

Renal Cell Carcinoma Urothelial Carcinoma Cervical Cancer +2 more

UNKNOWN PHASE2

Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor

NCT00793871

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

COMPLETED PHASE4

Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors

NCT02133157

Tumor

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Famitinib Malate Capsules 10mg single dose

Intervention Type DRUG

Famitinib Malate Capsules

Famitinib Malate Capsules 15mg single dose

Intervention Type DRUG

Famitinib Malate Capsules

Famitinib Malate Capsules 20mg single dose

Intervention Type DRUG

Famitinib Malate Capsules

Famitinib Malate Capsules 10mg\*2 single dose

Intervention Type DRUG

Famitinib Malate Capsules

Famitinib Malate Capsules 25mg single dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Gender: healthy male and female subjects.
2. Age: 18 years old and above (including 18 years old).
3. Weight: male subjects should not be less than 50.0kg, female subjects should not be less than 45.0kg, body mass index \[BMI=weight (kg)/height2 (m2)\] is 19.0 to 26.0kg/m2 (including boundary values).
4. Subjects with fertility and their partners have no fertility plan and voluntarily take medically approved high-efficiency contraception methods (see appendix 1 for details), and no plan to donate eggs or sperm within 28 weeks after signing the informed consent. Women with childbearing potential must have a negative serum pregnancy test within 24 hours before taking the study drug for the first time.
5. Subjects must give informed consent to this study before the experiment, and voluntarily sign a written informed consent form.
6. The subject can communicate well with the researcher and can complete the research in accordance with the research regulations.

Exclusion Criteria

1. Those who are allergic to the active ingredients of the preparation and related compounds and any excipients or are allergic to two or more drugs (or food).
2. Those who cannot follow a unified diet (such as intolerance to standard meals, etc.).
3. Those who cannot tolerate venepuncture, and those who have a history of fainting needles and bleeding.
4. There is a history of cardiovascular (such as hypertension), liver, kidney (such as chronic kidney disease), endocrine, blood system, respiratory system, malignant tumour, mental abnormality, severe infection, etc. or the existing above diseases that the researcher judges to be clinically significant.
5. Chronic or active gastrointestinal diseases such as esophagitis, gastritis, gastric ulcer, enteritis, gastrointestinal bleeding, gastroesophageal reflux disease, gastrointestinal obstruction, oesophageal varices, or gastrointestinal surgery (part of the digestive tract resection, cholecystectomy), etc., and the investigator believes that there is still clinical significance.
6. During the screening period, there are serious gastrointestinal symptoms (such as nausea, vomiting, stomach pain, abdominal pain, diarrheal, abdominal discomfort, abdominal distension, etc.), and the investigator believes that it is currently clinically meaningful.
7. Patients with upper respiratory tract infection during the screening period, and the investigator believes that it is currently clinically significant.
8. Those who have undergone major surgery within 6 months before screening, or who plan to undergo surgery during the study period, and those who have undergone surgery that will affect drug absorption, distribution, metabolism, and excretion (except for appendicitis surgery).
9. During the screening period, physical examination, vital signs, 12-lead electrocardiogram, chest radiograph, abdominal ultrasound, blood routine, blood biochemistry, urine routine, blood coagulation and thyroid function (FT3, FT4, TSH) abnormalities, the investigator judged that the abnormalities have clinical significance.
10. Abnormal test results of hepatitis B surface antigen, hepatitis C virus antibody, Treponema pallidum antibody or human immunodeficiency virus antibody have clinical significance.
11. Those who drank excessive amounts of tea, coffee, or caffeinated beverages (more than 8 cups a day, 1 cup = 200 mL) within 3 months before screening; or consumed any food or beverages containing caffeine within 48 hours before the first administration of the study drug (Such as coffee, strong tea, chocolate, etc.).
12. Those who have consumed any beverages or foods that are rich in xanthine or grapefruit ingredients or other beverages or foods that affect the absorption, distribution, metabolism, and excretion of the drug within 48 hours before the first administration of the study drug.
13. Any drug that interacts with this drug has been used within 4 weeks before screening (see appendix 3).
14. Those who have used long-acting estrogen or progestin injections or implants within 6 months before the test; those who have used short-acting contraceptives within 30 days before the test.
15. Those who have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or health care products in the 14 days before the first administration of the study drug.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes